Proceedings of the National Academy of Sciences · 2022 · 100 citations · 55 references
Life SciencesBiochemistryPharmacologyBiochemical PharmacologyMetabolic RegulationMetabolismDiabetes ManagementDiabetes MellitusDiabetes Mellitus BiochemistryDiabetes PharmacotherapyGluconeogenesis RegulationGlycemic ControlAntidiabetic ActivityAntidiabetic Drug TherapyCytosolic Redox HomeostasisDiabetes Mellitus MetabolismGluconeogenesisGluconeogenesis InhibitionGlucose-lowering TherapyHepatic Gluconeogenesis
SignificanceMetformin is the most commonly prescribed drug for the treatment of type 2 diabetes mellitus, yet the mechanism by which it lowers plasma glucose concentrations has remained elusive. Most studies to date have attributed metformin's glucose-lowering effects to inhibition of complex I activity. Contrary to this hypothesis, we show that inhibition of complex I activity in vitro and in vivo does not reduce plasma glucose concentrations or inhibit hepatic gluconeogenesis. We go on to show that metformin, and the related guanides/biguanides, phenformin and galegine, inhibit complex IV activity at clinically relevant concentrations, which, in turn, results in inhibition of glycerol-3-phosphate dehydrogenase activity, increased cytosolic redox, and selective inhibition of glycerol-derived hepatic gluconeogenesis both in vitro and in vivo.
55
Role of AMP-activated protein kinase in mechanism of metformin action
Gaochao Zhou, Robert P. Myers, Ying Li et al. · Journal of Clinical Investigation · 2001 · 5.4K citations
The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Reuben J. Shaw, Katja Lamia, Debbie S. Vasquez et al. · Science · 2005 · 1.9K citations